Polyglucosamine

DEVICE3 trials

Sponsors

Certmedica International GmbH

Conditions

Atherosclerotic DiseaseObesityOverweightOverweight and Obesity

Unknown Phase

Efficacy of Polyglucosamine for Weight Loss

CompletedNCT02410785

Certmedica International GmbHOverweight and Obesity

Start: 2009-08-31End: 2010-10-31Updated: 2016-01-28

RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

CompletedNCT02529631

Certmedica International GmbHObesity, Overweight

Start: 2009-11-30End: 2013-08-31Updated: 2015-08-20

CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)

Not yet recruitingNCT06910111

Certmedica International GmbHAtherosclerotic Disease

Start: 2025-04-01End: 2027-03-31Target: 240Updated: 2025-04-04

Related Papers

Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity.

2017-01-114 citations

Efficacy of polyglucosamine for weight loss—confirmed in a randomized double-blind, placebo-controlled clinical investigation

BMC Obesity2015-06-0926 citations